A Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of PD5K3 in Healthy Adult Volunteers
Latest Information Update: 05 Aug 2024
At a glance
- Drugs PD 5K3 (Primary) ; Pegaspargase
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Chongqing Peg-Bio Biopharm
Most Recent Events
- 05 Aug 2024 New trial record